CTI BioPharma Corp. (CTIC) Short Interest Down 26.0% in September
CTI BioPharma Corp. (NASDAQ:CTIC) was the target of a large decline in short interest during the month of September. As of September 15th, there was short interest totalling 776,821 shares, a decline of 26.0% from the August 31st total of 1,049,111 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average trading volume of 707,501 shares, the days-to-cover ratio is currently 1.1 days.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Blair William & Co. IL purchased a new position in shares of CTI BioPharma Corp. during the second quarter worth about $174,000. Commerzbank Aktiengesellschaft FI boosted its position in shares of CTI BioPharma Corp. by 1.1% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 425,986 shares of the biopharmaceutical company’s stock worth $145,000 after buying an additional 4,526 shares during the period. BVF Inc. IL boosted its position in shares of CTI BioPharma Corp. by 2.3% in the first quarter. BVF Inc. IL now owns 44,796,940 shares of the biopharmaceutical company’s stock worth $23,805,000 after buying an additional 1,001,327 shares during the period. Geode Capital Management LLC boosted its position in shares of CTI BioPharma Corp. by 20.0% in the first quarter. Geode Capital Management LLC now owns 1,321,080 shares of the biopharmaceutical company’s stock worth $702,000 after buying an additional 220,343 shares during the period. Finally, State Street Corp boosted its position in shares of CTI BioPharma Corp. by 9.5% in the first quarter. State Street Corp now owns 2,730,387 shares of the biopharmaceutical company’s stock worth $1,452,000 after buying an additional 237,602 shares during the period. 28.96% of the stock is currently owned by institutional investors and hedge funds.
CTI BioPharma Corp. (NASDAQ:CTIC) opened at 0.3743 on Friday. The stock’s market cap is $104.66 million. The stock’s 50 day moving average price is $0.37 and its 200-day moving average price is $0.42. CTI BioPharma Corp. has a one year low of $0.25 and a one year high of $1.75.
CTI BioPharma Corp. (NASDAQ:CTIC) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. CTI BioPharma Corp. had a negative net margin of 133.07% and a negative return on equity of 268.19%. On average, analysts predict that CTI BioPharma Corp. will post ($0.19) earnings per share for the current year.
CTIC has been the topic of a number of recent research reports. Zacks Investment Research cut CTI BioPharma Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, July 13th. Piper Jaffray Cos. restated a “neutral” rating and issued a $0.75 target price on shares of CTI BioPharma Corp. in a report on Monday, August 29th.
CTI BioPharma Corp. Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Stock Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related stocks with our FREE daily email newsletter.